|
|
Prepublished online as a Blood First Edition Paper on October 10, 2002; DOI 10.1182/blood-2002-04-1261.
Submitted April 29, 2002
Accepted September 20, 2002
Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study
Catherine Metayer, Rochelle E Curtis*, Julie Vose, Kathleen A Sobocinski, Mary M Horowitz, Smita Bhatia, Joseph W Fay, Cesar O Freytes, Steven C Goldstein, Roger H Herzig, Armand Keating, Carol B Miller, Thomas J Nevill, Andrew L Pecora, J D Rizzo, Stephanie F Williams, Chin-Yang Li, Lois B Travis, and Daniel J Weisdorf
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
University of Nebraska Medical Center, Omaha, NE, USA
Autologous Blood and Bone Marrow Transplant Registry, Medical College of Wisconsin, Milwaukee, WI, USA
City of Hope National Medical Center, Duarte, CA, USA
Baylor University Medical Center, Dallas, TX, USA
University of Texas, Health Science Center, San Antonio, TX, USA
H. Lee Moffitt Cancer Center, Tampa, FL, USA
University of Louisville Hospital, Louisville, KE, USA
the Princess Margaret Hospital/Ontario Cancer Institute, Toronto, ON, Canada
Johns Hopkins Oncology Center, Baltimore, MD, USA
British Columbia Cancer Agency and Vancouver General Hospital, Vancouver, BC, Canada
the Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA
University of Chicago Medical Center, Chicago, IL, USA
Mayo Clinic, Rochester, MN, USA
University of Minnesota Medical School, Minneapolis, MN, USA
* Corresponding author; email: curtisr{at}epndce.nci.nih.gov.
Although numerous reports indicate that patients receiving autotransplants for lymphoma are at increased risk for myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), the separate contributions of pre-transplant and transplant-related therapy are not well characterized. We conducted a case-control study of 56 patients with MDS/AML and 168 matched controls within a cohort of 2,739 patients receiving autotransplants for Hodgkin disease or non-Hodgkin lymphoma at 12 institutions (1989-1995). Detailed abstraction of medical records was undertaken to determine all pre- and post-transplant therapy, and transplant-related procedures. In multivariate analyses, risks of MDS/AML significantly increased with the intensity of pre-transplant chemotherapy including mechlorethamine (relative risks [RR] = 2.0 and 4.3 for cumulative doses < 50 mg/m2 and  50 mg/m2, respectively, P trend = 0.04) or chlorambucil (RRs = 3.8 and 8.4 for duration <10 months or 10 months, respectively, P trend = 0.009), compared with cyclophosphamide-based therapy. Transplant conditioning regimens including total-body irradiation (TBI) at doses  12 Gy did not appear to elevate leukemia risk (RR = 1.4, P = 0.46) compared with non-TBI regimens; however, a statistically significant increased risk was found for TBI doses of 13.2 Gy (RR = 4.7, P = 0.03). Peripheral blood stem cells were associated with a non-significant increased risk of MDS/AML (RR = 1.8, P = 0.12) compared with bone marrow grafts. Our data show that type and intensity of pre-transplant chemotherapy with alkylating agents are important risk factors of MDS/AML following autotransplantation. Transplant-related factors may also modulate this risk; however, the apparent contribution of high-dose TBI requires confirmation.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. K. Funk, T. J. Maxwell, M. Izumi, D. Edwin, F. Kreisel, T. J. Ley, J. M. Cheverud, and T. A. Graubert
Quantitative trait loci associated with susceptibility to therapy-related acute murine promyelocytic leukemia in hCG-PML/RARA transgenic mice
Blood,
August 15, 2008;
112(4):
1434 - 1442.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. S. Majhail
Old and New Cancers after Hematopoietic-Cell Transplantation
Hematology,
January 1, 2008;
2008(1):
142 - 149.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Bhatia, L. Francisco, A. Carter, C.-L. Sun, K. S. Baker, J. G. Gurney, P. B. McGlave, A. Nademanee, M. O'Donnell, N. K. C. Ramsay, et al.
Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study
Blood,
November 15, 2007;
110(10):
3784 - 3792.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Leone, L. Pagano, D. Ben-Yehuda, and M. T. Voso
Therapy-related leukemia and myelodysplasia: susceptibility and incidence
Haematologica,
October 1, 2007;
92(10):
1389 - 1398.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Nash, P. A. McSweeney, L. J. Crofford, M. Abidi, C.-S. Chen, J. D. Godwin, T. A. Gooley, L. Holmberg, G. Henstorf, C. F. LeMaistre, et al.
High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study
Blood,
August 15, 2007;
110(4):
1388 - 1396.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Z.S. Rohatiner, L. Nadler, A. J. Davies, J. Apostolidis, D. Neuberg, J. Matthews, J. G. Gribben, P. M. Mauch, T. A. Lister, and A. S. Freedman
Myeloablative Therapy With Autologous Bone Marrow Transplantation for Follicular Lymphoma at the Time of Second or Subsequent Remission: Long-Term Follow-Up
J. Clin. Oncol.,
June 20, 2007;
25(18):
2554 - 2559.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Gopal, J. G. Rajendran, T. A. Gooley, J. M. Pagel, D. R. Fisher, S. H. Petersdorf, D. G. Maloney, J. F. Eary, F. R. Appelbaum, and O. W. Press
High-Dose [131I]Tositumomab (anti-CD20) Radioimmunotherapy and Autologous Hematopoietic Stem-Cell Transplantation for Adults >= 60 Years Old With Relapsed or Refractory B-Cell Lymphoma
J. Clin. Oncol.,
April 10, 2007;
25(11):
1396 - 1402.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Brusamolino and A. M. Carella
Treatment of refractory and relapsed Hodgkin's lymphoma: facts and perspectives
Haematologica,
January 1, 2007;
92(1):
6 - 10.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Sebban, N. Mounier, N. Brousse, C. Belanger, P. Brice, C. Haioun, H. Tilly, P. Feugier, R. Bouabdallah, C. Doyen, et al.
Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
Blood,
October 15, 2006;
108(8):
2540 - 2544.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kalaycio, L. Rybicki, B. Pohlman, R. Sobecks, S. Andresen, E. Kuczkowski, and B. Bolwell
Risk Factors Before Autologous Stem-Cell Transplantation for Lymphoma Predict for Secondary Myelodysplasia and Acute Myelogenous Leukemia
J. Clin. Oncol.,
August 1, 2006;
24(22):
3604 - 3610.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Copelan
Hematopoietic stem-cell transplantation.
N. Engl. J. Med.,
April 27, 2006;
354(17):
1813 - 1826.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J P A Samijn, P A W te Boekhorst, T Mondria, P A van Doorn, H Z Flach, F G A van der Meche, J Cornelissen, W C Hop, B Lowenberg, and R Q Hintzen
Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis
J. Neurol. Neurosurg. Psychiatry,
January 1, 2006;
77(1):
46 - 50.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. F. Khouri
Reduced-Intensity Regimens in Allogeneic Stem-Cell Transplantation for Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Hematology,
January 1, 2006;
2006(1):
390 - 397.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Forrest, D. E. Hogge, T. J. Nevill, S. H. Nantel, M. J. Barnett, J. D. Shepherd, H. J. Sutherland, C. L. Toze, C. A. Smith, J. C. Lavoie, et al.
High-Dose Therapy and Autologous Hematopoietic Stem-Cell Transplantation Does Not Increase the Risk of Second Neoplasms for Patients With Hodgkin's Lymphoma: A Comparison of Conventional Therapy Alone Versus Conventional Therapy Followed by Autologous Hematopoietic Stem-Cell Transplantation
J. Clin. Oncol.,
November 1, 2005;
23(31):
7994 - 8002.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Lavoie, J. M. Connors, G. L. Phillips, D. E. Reece, M. J. Barnett, D. L. Forrest, R. D. Gascoyne, D. E. Hogge, S. H. Nantel, J. D. Shepherd, et al.
High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver
Blood,
August 15, 2005;
106(4):
1473 - 1478.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Bhatia, L. L. Robison, L. Francisco, A. Carter, Y. Liu, M. Grant, K. S. Baker, H. Fung, J. G. Gurney, P. B. McGlave, et al.
Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study
Blood,
June 1, 2005;
105(11):
4215 - 4222.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Vose, P. J. Bierman, C. Enke, J. Hankins, G. Bociek, J. C. Lynch, and J. O. Armitage
Phase I Trial of Iodine-131 Tositumomab With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation for Relapsed Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
January 20, 2005;
23(3):
461 - 467.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tichelli and G. Socie
Considerations for Adult Cancer Survivors
Hematology,
January 1, 2005;
2005(1):
516 - 522.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Lenz, M. Dreyling, E. Schiegnitz, T. Haferlach, J. Hasford, M. Unterhalt, and W. Hiddemann
Moderate Increase of Secondary Hematologic Malignancies After Myeloablative Radiochemotherapy and Autologous Stem-Cell Transplantation in Patients With Indolent Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group
J. Clin. Oncol.,
December 15, 2004;
22(24):
4926 - 4933.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Montoto, A. Lopez-Guillermo, A. Altes, G. Perea, A. Ferrer, M. Camos, L. Villela, F. Bosch, J. Esteve, F. Cervantes, et al.
Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression
Ann. Onc.,
October 1, 2004;
15(10):
1484 - 1489.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Czyz, R. Dziadziuszko, W. Knopinska-Postuszuy, A. Hellmann, L. Kachel, J. Holowiecki, J. Gozdzik, J. Hansz, A. Avigdor, A. Nagler, et al.
Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients
Ann. Onc.,
August 1, 2004;
15(8):
1222 - 1230.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. N. Winter, R. D. Gascoyne, and K. Van Besien
Low-Grade Lymphoma
Hematology,
January 1, 2004;
2004(1):
203 - 220.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. van Besien, F. R. Loberiza Jr, R. Bajorunaite, J. O. Armitage, A. Bashey, L. J. Burns, C. O. Freytes, J. Gibson, M. M. Horowitz, D. J. Inwards, et al.
Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma
Blood,
November 15, 2003;
102(10):
3521 - 3529.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Gopal, T. A. Gooley, D. G. Maloney, S. H. Petersdorf, J. F. Eary, J. G. Rajendran, S. A. Bush, L. D. Durack, J. Golden, P. J. Martin, et al.
High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis
Blood,
October 1, 2003;
102(7):
2351 - 2357.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Tallman, R. Gray, N. J. Robert, C. F. LeMaistre, C. K. Osborne, W. P. Vaughan, W. J. Gradishar, T. M. Pisansky, J. Fetting, E. Paietta, et al.
Conventional Adjuvant Chemotherapy with or without High-Dose Chemotherapy and Autologous Stem-Cell Transplantation in High-Risk Breast Cancer
N. Engl. J. Med.,
July 3, 2003;
349(1):
17 - 26.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. F. Storb, G. Lucarelli, P. A. McSweeney, and R. W. Childs
Hematopoietic Cell Transplantation for Benign Hematological Disorders and Solid Tumors
Hematology,
January 1, 2003;
2003(1):
372 - 397.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
